Movement Disorders / Parkinson's Disease


click here to return to the Clinical Trials page


Ongoing Clinical Trials


IRB 17-0446 BMS PSP Phase 2
  • This study is looking for subjects with Progressive Supranuclear Palsy (PSP) to test a new drug. We will collect clinical information, demographics, samples of blood and MRI images.
  • Eligibility: PSP patients between 45-85 yrs, with PSP symptoms for no more than 5 years, must be able to ambulate 10 steps independently.
  • Visits: 1-2 screening visits to determine eligibility. 13 visits in first year receive intravenous (IV) infusion every 4 weeks (of placebo or drug). After the first year, you will have the option to continue receiving IV infusions of drug (no risk of placebo) indefinitely.
  • Funding: sponsor company Bristol Myer’s Squibb.
  • Principal Investigator: Tao Xie MD PhD

IRB 16-1780 AbbVie PSP Phase 1
  • This study is looking for subjects with Progressive Supranuclear Palsy (PSP to test a new drug. We will collect clinical information, demographics, samples of blood and MRI images.
  • Eligibility: PSP patients between 45-85 yrs, with PSP symptoms for no more than 5 years, must be able to ambulate 5 steps independently.
  • Visits: 2-3 screening visits to determine eligibility. 17 visits in first year receive intravenous (IV) infusion every 4 weeks (of placebo or drug), 14 infusions total with 3 safety visits not including IVs. This sponsor will provide the option of being a part of an open-label extension.
  • Funding: sponsor company AbbVie.
  • Principal Investigator: Tao Xie MD PhD

IRB 17-0998 PD-AA
  • This study is looking for subjects with confirmed diagnosis of Parkinson’s Disease (PD) in patients of African American or Caucasian background to study the clinical features and genetic profile of African American patients with PD.
  • Eligibility: PD patients above 45 yrs.
  • Visits: 1 visit will be needed to complete all study assessments, this will be done in standard clinic. We will complete a series of assessments, collect demographic information and PD history, and will draw 2 tubes of blood for genetic testing.
  • Funding: sponsor company The National Parkinson Foundation.
  • Principal Investigator: Tao Xie MD PhD

Fox Investigation for New Discovery of Biomarkers (BioFIND)
  • This study is looking for subjects with Parkinson’s disease (PD) and healthy volunteers. We will collect clinical information, samples of blood, and cerebral spinal fluid (spinal tap).
  • Eligibility: PD subjects between the ages of 55 to 93 years old, with PD symptoms for 5 to 15 years.
  • Visits: two visits to our center within approximately two weeks.
  • Funding: The Micheal J. Fox Foundation for Parkinson’s Research (MJFF) and supported by NINDS and NIH.
  • Principal Investigator: Tao Xie MD PhD

Biomarkers In Parkinson’s Disease
  • This study is looking for subjects with Parkinson’s disease (PD) and healthy volunteers. We will collect clinical information and blood samples.
  • Eligibility: Subjects between 30 and 85 years of age.
  • Visits: one visit to our center.
  • Funding: The American Parkinson’s Disease Association (APDA).
  • Principal Investigator: Tao Xie MD PhD

Dystonia Coalition Projects
  • The purpose of this study is to create a “repository” or an organized collection of medical data and samples to be used for future research on dystonia and other diseases. We will collect information, videos and blood samples from adults who have dystonia or related disorders and store this in the repository.
  • Eligibility: Subjects 18 years or older who have primary dystonia.
  • Visits: one visit to our center with follow-up visits yearly for those who have been diagnosed  with dystonia within the past five years.
  • Funding: The National Institute of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) and the Office of Rare Diseases Research (ORDR).
  • Principal Investigator: Tao Xie MD PhD

Characterization of the Parkinsonism and Other Non-Ataxia Spectrum and Striatal Dopaminergic Degeneration in Spinocerebeller Ataxia (SCA) type 6
  • The purpose of this study is to study possible parkinsonism in patients with spinocerebeller ataxia type 6 (SCA-6). We will collect clinical information and a SPECT DaTscan (brain scan).
  • Eligibility: Subjects with SCA-6 ataxia and healthy volunteers 18 years old and older.
  • Visits: two visits to our center.
  • Funding: GE Healthcare.
  • Principal Investigators: Tao Xie MD PhD; Jacqueline Bernard MD; Christopher Gomez MD PhD

Improving the Care of Patients with Psychogenic Movement Disorders: A Model Involving in Depth Communication Between the Movement Disorder Specialist, Psychiatrist and the Patient
  • The purpose of this study is to provide a new therapeutic model for improved treatment of this condition by enhancing communication between the movement disorder specialist, psychiatrist and the patient. This study involves questionnaires, clinical exams and videotaping of the subjects movements.
  • Eligibility: Subjects 16 years old or older.
  • Visits: Four visits to our center. Subjects will have two visits with the movement disorder specialist and two visits the psychiatrist, after enrolling into the study.
  • Funding: The Bucksbaum Institute of Clinical Excellence at the University of Chicago.
  • Principal Investigator: Tao Xie MD PhD and Marie Tobin MD

Effects of the Stimulation Frequency of the STN DBS on Swallowing Function and Freezing of Gait in Patients with Parkinson’s Disease: An Extended Chronic Phase Study
  • This study is the extension of the one we have just completed (see Completed Students), but with longer period of follow up for at least 6 months.
  • Principal Investigator: Tao Xie MD PhD

 


Completed Studies


A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

  • The purpose of this study was to find out the efficacy and safety of davunetide given intranasally to patients with Progressive Supranuclear Palsy (PSP).  This global study (we were the only site in the State of Illinois) was done. The study found no therapeutic effect of this medication on PSP, though the medication was safe.
  • Principal Investigator: Tao Xie MD PhD

Effects of the Stimulation Frequency of the STN DBS on Swallowing Function and Freezing of Gait in Patients with Parkinson’s Disease

  • The purpose of this study is to evaluate swallowing function and freezing of gait in patients with bilateral subthalamic nucleus deep brain stimulation (STN DBS). Swallowing function would be tested at the study visits using different frequency settings of the DBS.
  • Eigibility: Subjects would be 45 years old and older, who have had their DBS device for over six months.
  • Visits: two visits to our center approximately six to eight weeks apart. Study subjects would have a total of four swallowing tests, timed walk tests and questionnaires at the study visits.
  • Funding: The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
  • Principal Investigator: Tao Xie MD PhD
  • Results: This study has proven that low frequency stimulation of 60Hz helps to improve swallowing function, freezing of gait and other axial symptoms, compared to the routine 130Hz stimulation. A paper will be published in the green journal Neurology soon.